WO2014049821A1 - Medical system - Google Patents

Description

Medical system

The present invention relates to a medical system for introducing mononuclear cells, which are angiogenic factors, into a living body over time.

When arteriosclerosis or thrombus is formed and the state where the blood vessel is obstructed chronically continues, blood circulation failure occurs around the occluded site or at a site downstream of the occluded blood flow. In addition, when blood circulation failure occurs, an ischemic state is caused, and the ischemic state is sustained, and necrosis is caused in the living tissue. In recent years, as a treatment method for such vascular occlusion, there is a treatment method for improving blood circulation by introducing an angiogenic factor around an ischemic site to develop a collateral circulation path to an artery present in the ischemic site. Proposed.

As a technique related to the above therapeutic method, Patent Document 1 below discloses an angiogenic agent containing hydrogel particles carrying an angiogenic factor and a method for introducing the same. In this treatment method using an angiogenic agent, a hydrogel particle is introduced transarterially into a poorly developed collateral circulation using a medical device such as a catheter, and the hydrogel particle is introduced into a blood vessel in a predetermined manner. It is allowed to stay for a period to promote the development of collateral circulation. By developing collateral circulation, blood flow at the ischemic site is increased to try to treat ischemic diseases.

JP-A-2005-104910

When the above-mentioned angiogenic agent is placed in a blood vessel, hydrogel particles disappear irregularly and disperse, so that there is a possibility that the effect of developing collateral circulation cannot be obtained sufficiently. For this reason, it is necessary to continuously administer the angiogenic agent in a relatively short period of time. In connection with this, the number of times the catheter is introduced into the living body, and the living body is punctured to introduce the catheter. Since the frequency | count etc. will increase, the burden to the patient used as administration object will become large.

The present invention has been made in view of the above-described problems, and enables mononuclear cells that are angiogenic factors to be supplied into the living body over time, thereby reducing the burden on patients associated with the treatment of ischemic diseases. It aims at providing the medical system which can be reduced.

(1) A medical system that introduces mononuclear cells, which are angiogenic factors, into a living body over time, the sustained-release unit provided so that the mononuclear cells can be released in vivo, and the sustained-release unit A medical system comprising: a catheter for introducing a mononuclear cell into a living body; and a supply unit that is connected to the catheter and supplies the mononuclear cells to the sustained-release unit via the catheter.

(2) The sustained-release part includes a container structure in which the mononuclear cell can be accommodated and a through-hole for allowing the mononuclear cell to be gradually released from the accommodation part to the outside of the accommodation part. The medical system according to (1) above.

(3) The medical system according to (2), wherein the through hole provided in the sustained-release portion is formed to have a diameter of 12 to 20 μm.

(4) In the state in which the supply unit is disposed in the collateral circulation path located on the central side of the living body relative to the ischemic site formed in the living body or in the peripheral portion of the collateral circulation path The medical system according to any one of (1) to (3), wherein the supply of the mononuclear cells is performed over time.

(5) The medical system according to any one of (1) to (4), wherein the sustained release portion has a long shape that can be wound around the blood vessel and disposed.

According to the invention described in (1) above, since the mononuclear cells can be gradually released from the sustained release part introduced into the living body over time, the intravascular flow of the patient can be reduced within the treatment period of the ischemic disease. The number of times of introducing the medical device can be reduced, and the burden on the patient accompanying the treatment of the ischemic disease can be reduced.

According to the invention described in the above (2), it is possible to hold the mononuclear cells in the accommodating portion provided in the sustained release portion, and to further release the mononuclear cells from the sustained release portion over time. Therefore, the mononuclear cells can be retained in the blood vessel for a relatively long period of time while releasing the mononuclear cells gradually.

According to the invention described in (3) above, it is possible to suitably release monocytes from the housing part provided in the sustained release part.

According to the invention described in (4) above, the growth of the collateral circulation can be promoted so as to extend to the ischemic site, and the blood circulation in the ischemic site can be improved efficiently.

According to the invention described in (5) above, since it is possible to supply mononuclear cells around the blood vessel, it promotes the growth of blood vessels and forms angiogenesis around the blood vessels. The effect | action which performs can be improved.

It is a figure showing simplified the whole composition of the medical system concerning the embodiment of the present invention. It is a figure for demonstrating the use condition of the medical system which concerns on embodiment. It is a figure which expands and shows the sustained release part with which the medical system which concerns on embodiment is provided. It is a figure which shows typically the lower limb of the biological body in which the ischemic site | part was formed. It is a figure for demonstrating the effect | action of the medical system which concerns on embodiment, Comprising: It is a figure which simplifies and shows a mode that the sustained release part with which a medical system is provided was introduced into the artery. It is a figure for demonstrating the effect | action of the medical system which concerns on embodiment, Comprising: It is a figure which simplifies and shows a mode that a mononuclear cell is sustainedly released from the sustained release part with which a medical system is provided. It is a figure for demonstrating the effect | action of the medical system which concerns on embodiment, Comprising: It is the elements on larger scale which show typically a mode after the mononuclear cell is sustainedly released from the sustained release part with which a medical system is provided. It is a figure for demonstrating the effect | action of the medical system which concerns on embodiment, Comprising: It shows typically a mode that the growth of a collateral circulation is accelerated | stimulated by the mononuclear cell slowly released from the sustained release part with which a medical system is equipped. It is a partial enlarged view. It is a figure which shows typically the lower limb of the biological body by which the growth of the collateral circulation was promoted by the medical system which concerns on embodiment. It is a figure which shows the modification 1 of the medical system which concerns on embodiment. It is a figure which shows the modification 2 of the medical system which concerns on embodiment.

Hereinafter, the present invention will be described based on embodiments with reference to the drawings. 1 to 3 are diagrams for explaining each configuration of the medical system according to the embodiment, and FIGS. 4 to 8 are diagrams for explaining the operation of the medical system according to the embodiment. In the description of the drawings, the same elements are denoted by the same reference numerals, and redundant description is omitted. In addition, the dimensional ratios in the drawings are exaggerated for convenience of explanation, and may be different from the actual ratios.

Referring to FIG. 1, a medical system 10 according to an embodiment of the present invention is a medical system 10 that introduces a mononuclear cell 140 as an angiogenic factor into a living body over time. The sustained release part 20 provided so that the sphere 140 can be gradually released in the living body, the catheter 30 for introducing the sustained release part 20 into the living body, the catheter 30, and the sustained release part 20 via the catheter 30. And a supply unit 40 for supplying the mononuclear sphere 140 to the surface.

Referring to FIG. 4, an ischemic disease to be treated by the medical system 10 will be briefly described. FIG. 4 schematically shows a lower limb 50 of a patient suffering from an ischemic disease. In the figure, the central side (upper side in the figure) of the living body with respect to the broken line part A indicates a site P1 in which normal blood flow is secured, and the peripheral side of the living body with respect to the broken line part A (lower side in the figure). Indicates ischemic site P2.

Ischemic disease is caused by the formation of stenotic sites in the blood vessels that interfere with blood flow such as arteriosclerosis and thrombus. This is a disease in which such a site becomes chronically ischemic. In addition, persistence of the ischemic state causes necrosis of living tissue. In the illustrated example, a stenotic site N or the like is formed for some reason in an artery such as the external iliac artery 60 or the like that inherently has a function of distributing blood to the peripheral part of the lower limb 50 of a living body, and sufficient blood to the peripheral side is formed. As a result, it becomes impossible to secure the flow, and a state in which the ischemic site P2 is formed due to this is shown.

The medical system 10 is used to improve and treat an ischemic disease by supplying a mononuclear cell as an angiogenic factor into a blood vessel of a patient suffering from an ischemic disease with time. More specifically, a mononuclear cell is supplied to an ungrown collateral blood circulation 70 (a small-sized artery at the periphery of an artery, for example, an internal iliac artery), and the collateral blood circulation 70 is transmitted by the mononuclear cell. Is connected to an artery such as the inferior arterial artery 78 of the ischemic site P2, and the blood flowing through the external iliac artery 60 is diverted to the ischemic site P2 by bypassing the stenotic site N, thereby increasing the blood flow at the ischemic site P2. Make it possible. In the specification, “promoting the growth of blood vessels (collateral circulation)” means extending the peripheral side of the blood vessels, increasing the diameter of the blood vessels, or renewing the blood vessels.

As mononuclear cells supplied by the medical system 10, those existing in body fluids and blood (bone marrow fluid, peripheral blood, umbilical cord blood, etc.) that are basic fibroblast growth factor (bFGF) precursors should be used. Can do. For example, mononuclear cells (lymphocytes, NK spheres, NKT cells, monocytes, etc.) obtained by removing red blood cells, platelets, granulocytes and the like from blood and further separating and concentrating them can be used. Separation and concentration can be performed by, for example, a known blood component separation device using a filter or centrifugal separation.

Next, each configuration of the medical system 10 will be described.

With reference to FIG. 1, the medical system 10 is additionally provided with various components for improving the usability of the medical system 10 in addition to the sustained release unit 20, the catheter 30, and the supply unit 40. be able to. As such additional components, the medical system 10 includes a replenishment system 110 for replenishing the supply unit 40 with the mononuclear cells 140 and a fixing member 120 for stably attaching the medical system 10 to a living body. ing.

The replenishment system 110 includes a connecting portion 111 that can be connected to and separated from the supply portion 40, a holding back 113 configured to hold a predetermined amount of mononuclear sphere 140, a holding back 113, and the connecting portion 111. A tube 115 that is tightly and airtightly connected, and a connector portion 117 provided on the tube 115 are provided.

The connection part 111 with which the replenishment system 110 is provided has a needle structure, and is configured to be able to puncture the sealing part 41 constituting the lid of the supply part 40. The supply unit 40 and the replenishment system 110 can be connected by causing the sealing unit 41 to puncture the connection unit 111.

When the mononuclear cells 140 are supplied from the supply unit 40 to the blood vessels of the living body and the amount of the mononuclear cells 140 held in the supply unit 40 decreases, the mononuclear cells are supplied to the supply unit 40 via the replenishment system 110. The sphere 140 can be replenished. The connector 117 can be connected to a syringe pump or the like known in the medical field. Therefore, it is also possible to replenish the mononuclear sphere 140 to the supply unit 40 using a syringe pump or the like.

The fixing member 120 is provided to fix the replenishment system 110 to the living body. FIG. 2 shows a simplified state in which the medical system 10 is used while being attached to a living body. The fixing member 120 is attached to the connection part 111 of the replenishment system 110, and allows the connection part 111 to be fixed to the body surface 90 of the living body in a state where the connection part 111 is connected to the supply part 40. For example, the fixing member 120 can be spread like a wing as illustrated, and an adhesive layer or the like can be provided on the surface facing the body surface 90. In addition, when the supply part 40 is attached to the biological surface 90, the cover material 121 which covers the supply part 40 can also be used. When the cover material 121 is used, the fixing member 120 is used so as to fix the connecting portion 111 to the surface of the cover material 121.

As illustrated in FIG. 3, the sustained release unit 20 included in the medical system 10 is configured to release the mononuclear sphere 140 from the storage unit 21 that can store the mononuclear sphere 140 and the storage unit 21 to the outside of the storage unit 21. It can comprise so that the container structure provided with this through-hole 23 may be provided. The sustained release portion 20 is appropriately provided with a connector 25 to which the catheter 30 can be connected. The connector 25 can be configured by a mechanical connector that can fix the distal end of the catheter 30 by fitting or screwing, for example. When the mononuclear sphere 140 is supplied to the sustained release unit 20 via the catheter 30, the mononuclear sphere 140 is temporarily held in the storage unit 21 provided in the sustained release unit 20. Then, the mononuclear sphere 140 is gradually released through each through hole 23 of the gradual release portion 20 as time elapses.

The sustained release portion 20 can be configured to have an outer shape that extends in the longitudinal direction, as shown. If comprised in this way, when the sustained release part 20 is introduce | transduced in the living body, since it becomes possible to release the mononuclear cell 140 from various places of a longitudinal direction, the sustained release property of the mononuclear cell 140 is improved. To facilitate the development of angiogenesis.

The through hole 23 provided in the sustained release portion 20 is not particularly limited as long as the mononuclear sphere 140 can pass through, but can be formed to have a diameter of 12 to 20 μm, for example. The reason for forming such a diameter is as follows. The monocytes contained in the mononuclear cells 140 effectively act as components that promote angiogenesis, but generally the average diameter of these monocytes is 12 to 20 μm. Therefore, by forming the through-hole 23 with the above diameter, monocytes can be efficiently and gradually released in the blood vessel, and the promotion of angiogenesis can be improved. In addition, the length dimension of the sustained release part 20 is not particularly limited, and can be appropriately changed according to the size of a living organ (for example, blood vessel) into which the sustained release part 20 is introduced.

Although there is no restriction | limiting in particular as the material which comprises the sustained release part 20, For example, as a metal material, stainless steel, a tantalum or a tantalum alloy, platinum or a platinum alloy, gold or a gold alloy, a cobalt base alloy, a cobalt chromium alloy, titanium An alloy, a niobium alloy, etc. are mentioned. Resin materials include polytetrafluoroethylene, polyethylene, polypropylene, polyethylene terephthalate, cellulose acetate, cellulose nitrate, polylactic acid, polyglycolic acid, copolymers of lactic acid and glycolic acid, polycaprolactone, polyhydroxybutyrate Examples thereof include biodegradable polymer materials such as valerate.

As shown in FIG. 1, the catheter 30 provided in the medical system 10 is provided such that one end side is connectable to the sustained release unit 20 and the other end side is connectable to the supply unit 40. As the connector 35 for connecting the catheter 30 and the supply unit 40, a fitting or screwing type connector can be used, similarly to the connector 25 for connecting the catheter 30 and the sustained release unit 20. As the catheter 30, a catheter 30 known in the medical field can be used. The material constituting the catheter 30 is not particularly limited. For example, polyvinyl chloride, polyethylene, polypropylene, cyclic polyolefin, polystyrene, poly (4-methylpentene-1), polycarbonate, acrylic resin, polyethylene terephthalate, polyethylene naphthalate. Various soft or hard resins such as polyester such as phthalate, butadiene-styrene copolymer, and polyamide (for example, nylon 6, nylon 6,6, nylon 6,10, nylon 12) can be used.

The supply unit 40 provided in the medical system 10 is configured by a port that holds the mononuclear sphere 140 and has a function of supplying the mononuclear sphere 140 into the catheter 30. The supply unit 40 operates to supply the mononuclear cell 140 to the catheter 30 according to a preset period. For example, the medical system 10 may be configured to include a control unit including a CPU or the like in which a program for controlling the operation of the supply unit 40 is incorporated in advance. By providing such a control means, it is possible to automatically control the start / end of the operation of the supply unit 40.

As shown in FIG. 2, when using the medical system 10, for example, the supply unit 40 is disposed on the biological surface 90, and the catheter 30 connected to the supply unit 40 and the sustained release unit 20 connected to the catheter 30 are: Each is percutaneously introduced into a blood vessel such as the collateral circulation 70.

Next, the operation of the medical system 10 will be described.

In the following description, an example in which the medical system 10 is applied to a patient with an ischemic disease in which the ischemic site P2 is formed on the lower limb 50 as shown in FIG.

First, prior to the introduction of the catheter 30 and the sustained release unit 20 into the blood vessel, the ischemic site P2 that is the site to be treated is specified. As a specifying method, a contrast examination or the like known in the medical field can be employed. Prior to performing a contrast examination, an access port for introducing a contrast agent into a blood vessel is appropriately provided in the living body. When the medical system 10 is used, for example, an access port can be provided at a position where the supply unit 40 of the medical system 10 is provided.

Next, as shown in FIG. 5, the sustained release portion 20 disposed at the distal end of the catheter 30 is guided to the collateral circulation path 70 located around the ischemic site P2. The introduction of the sustained release unit 20 into the collateral circulation 70 can be performed transvascularly via the femoral artery or the external iliac artery 60, for example.

As shown in FIG. 6, mononuclear cells 140 are supplied from the supply unit 40 to the sustained release unit 20 via the catheter 30. When the mononuclear cells 140 are supplied, the sustained release unit 20 gradually releases the mononuclear cells 140 into the collateral circulation 70. Note that not all mononuclear spheres 140 can be released slowly, and some of the mononuclear spheres 140 can be held in the accommodating portion 21 of the sustained release portion 20. In this manner, the growth of the collateral circulation 70 may be promoted from the vicinity of the position where the sustained release portion 20 is disposed. Further, when the sustained release portion 20 is formed in a container structure, monocytes contained in blood flowing in the collateral blood circulation path 70 can be captured and retained in the accommodating portion 21 of the sustained release portion 20. Therefore, the growth of the collateral circulation 70 can be promoted more effectively.

The mononuclear sphere 140 supplied to the sustained release unit 20 can be collected in advance by the above-described centrifugation method or the like. Moreover, it is preferable to use the mononuclear cells 140 collected from blood or bone marrow flowing through the peripheral blood vessels of the patient in consideration of biocompatibility to the patient.

As shown in FIG. 7A, the mononuclear cells 140 released from the sustained release unit 20 stay on the peripheral side 73 of the collateral circulation 70. Then, as time passes, as shown in FIG. 7B, the growth of the collateral circulation 70 is promoted by the mononuclear cells 140, so that the collateral circulation 70 grows from the peripheral side 73 ( The growth of the collateral circulation 70 is indicated by an arrow in the figure).

After the mononuclear cells 140 introduced into the collateral circulation 70 disappear, the mononuclear cells 140 are supplied again from the supply unit 40. By repeating the supply of the mononuclear cells 140 by the supply unit 40 over time, the growth of the collateral circulation 70 can be more effectively promoted.

By performing the above operation, as shown in FIG. 8, each collateral circulation path 70 into which the mononuclear cell 140 has been introduced grows so as to extend toward the knee joint artery 78 at the ischemic site P2. As a result, the collateral circulation 70 and the inferior knee artery 78 are connected, so that the external iliac artery 60 bypasses the stenotic site N and joins to the inferior artery 78. It becomes possible to supply blood from the external iliac artery 60 to the inferior artery 78, and blood circulation at the ischemic site P2 can be improved.

Thus, the method for treating ischemic disease according to the present embodiment includes the step of (i) introducing a mononuclear cell that becomes an angiogenic factor into a blood vessel of a living body over time.

In the step (i), the sustained release part capable of sustained release of mononuclear cells is disposed in the collateral circulation path located on the center side of the living body from the ischemic site formed in the living body. It is performed by supplying a mononuclear cell to a sustained-release part through this.

Further, the step (i) is performed a plurality of times during a predetermined period.

Also, the collateral circulation is the internal iliac artery.

As described above, according to the medical system 10 according to the present embodiment, the mononuclear cell 140 can be gradually released from the sustained release unit 20 introduced into the living body over time. The number of times the medical device is introduced into the blood vessel of the patient can be reduced, and the burden on the patient associated with the treatment of the ischemic disease can be reduced.

In addition, when the sustained release portion 20 is configured in a container structure including the accommodating portion 21 and the through hole 23, the mononuclear sphere 140 is held in the accommodating portion 21 provided in the sustained release portion 20, and the time Since the mononuclear cells 140 can be gradually released from the sustained release portion 20 with the progress, the mononuclear cells 140 are kept in the blood vessel for a relatively long time while the mononuclear cells 140 are gradually released. Is possible.

Further, when the diameter of the through hole 23 provided in the sustained release portion 20 is 12 to 20 μm, monocytes can be suitably released from the accommodating portion 21 provided in the sustained release portion 20.

In addition, the mononuclear cells 140 are supplied over time in a state where the sustained release portion 20 is disposed in the collateral circulation path 70 located on the center side of the living body with respect to the ischemic site P2 formed in the living body. When configured, the growth of the collateral circulation path 70 can be promoted so as to extend to the inferior knee artery 78 at the ischemic site P2, and the blood circulation at the ischemic site P2 can be improved efficiently.

Next, a modification of the above-described embodiment will be described. In addition, the description is abbreviate | omitted about the member same as the member demonstrated in embodiment mentioned above.

FIG. 9 shows a first modification of the medical system 10. In the above-described embodiment, the operation of supplying the mononuclear cells 140 is performed in a state where the sustained release portion 20 is disposed in the collateral circulation path 70. For example, as shown in the drawing, the sustained release portion 20 is connected to the collateral circulation. It is also possible to supply the mononuclear cell 140 in a state where it is disposed in the peripheral region 80 of the blood circulation path 70. As the peripheral portion 80, for example, a region between the distal side 73 of the collateral circulation 70 and the knee joint artery 78 can be selected as shown in the figure. By supplying the mononuclear cells 140 to such a site, it becomes possible to efficiently grow the collateral circulation 70 toward the inferior arteries 78, so that treatment is performed earlier after the mononuclear cells 140 are supplied. An effect can be obtained.

The introduction of the sustained release portion 20 into the peripheral portion 80 can be performed by, for example, operating the catheter 60 and the sustained release portion 20 to be screwed through a port or the like installed on the body surface. At the time of introduction, a guide catheter or a guide wire known in the medical field can be used in combination as appropriate. For easy understanding, the installation of the supply unit 40 is simplified in the figure.

As described above, according to the present modification, a new collateral circulation path 70 can be formed around the existing collateral circulation path 70, and therefore the number of branches of the collateral circulation path 70 is increased. In addition, the collateral blood circulation 70 and the inferior knee artery 78 are easily connected to each other, and as a result, the blood flow volume in the ischemic region P2 can be increased.

FIG. 10 shows a second modification of the medical system 10. In this modification, the sustained release portion 20 is formed in a long shape, and is further disposed so as to be wound around the collateral circulation path 70. By arranging the sustained release portion 20 in this manner, the mononuclear cells 140 can be supplied so as to be scattered around the collateral blood circulation 70, and therefore, the action of promoting the growth of the collateral blood circulation 70, The effect of forming angiogenesis around the collateral circulation 70 can be improved.

As the sustained-release part 20, the thing of the container structure provided with the accommodating part 21 and the through-hole 23 which were shown in embodiment mentioned above can be used. Further, the through-hole 23 may be formed only on the inner surface side that is disposed so as to face the collateral circulation path 70 so as to efficiently release the mononuclear cells 140 toward the collateral circulation path 70, for example. it can. In addition, the sustained release portion 20 is made of, for example, a flexible material so that the sustained release portion 20 can be easily wound around the collateral circulation path 70, or has a helical shape as shown in the figure. It can be configured in advance to be configured. For example, the sustained-release part 20 can be comprised with shape memory materials (metal etc.) etc. which form a predetermined shape with the temperature etc. in the living body.

The introduction of the sustained release portion 20 into the living body is performed by operating the catheter 60 and the sustained release portion 20 to be screwed through, for example, a port installed on the body surface, as in the first modification described above. it can. In addition, the same can be said for the introduction at the time of introduction by appropriately using a guide catheter or a guide wire known in the medical field.

In this way, by using the medical system 10, the sustained release part 20 capable of sustained release of the mononuclear cells 140 is located on the cervical side of the living body from the ischemic site P2 formed in the living body. The mononuclear cells 140 can be supplied to the sustained release unit 20 via the catheter 30 in a state where the mononuclear cells 70 are disposed in the peripheral region 80 of the collateral circulation path 70.

As described above, the medical system according to the present invention has been described based on the embodiments and a plurality of modified examples. However, the present invention is not limited only to these embodiments and modified examples, and is described in the claims. It is possible to change appropriately based on this.

For example, although the example in which the treatment method by the medical system 10 is applied to the collateral circulation 70 of the lower limb 50 has been shown, the part to be treated by the medical system 10 is not limited to such a part. The medical system 10 can be widely applied to parts other than the lower limb 50 for the purpose of supplying the mononuclear sphere 140 into the living body. In addition, the blood vessel to be applied is not limited to the internal iliac artery of the collateral blood circulation 70, and can be widely applied to various arteries and the like.

In addition, the medical system may include at least a sustained release unit, a catheter, and a supply unit so that mononuclear cells that become angiogenic factors can be introduced into the living body over time. Components such as the replenishment system 110 and the fixing member 120 can be omitted as appropriate. Further, the shape and structure of the sustained release part are not limited to those shown in the embodiment, and the supplied mononuclear cells can be appropriately changed as long as the sustained release (release) is possible.

10 Medical system,
20 Sustained release part,
21 containment section,
23 through hole,
30 catheter,
40 supply section,
50 lower limbs,
60 external iliac artery,
70 collateral circulation,
73 peripheral side of collateral circulation,
80 Peripheral area around the collateral circulation,
140 mononuclear spheres,
P1 normal site,
P2 ischemic site.

Claims (5)

A medical system that introduces mononuclear cells, which are angiogenic factors, into a living body over time,
A sustained release portion provided so that the mononuclear cells can be sustainedly released in vivo;
A catheter for introducing the sustained release portion into the living body;
And a supply unit connected to the catheter and supplying the mononuclear cells to the sustained-release unit via the catheter. The said sustained release part is equipped with the container structure in which the through-hole for making the said mononuclear sphere release gradually from the accommodating part which can accommodate the said mononuclear sphere, and the said accommodating part to the exterior of the said accommodating part is provided. Medical system as described in. The medical system according to claim 2, wherein the through-hole provided in the sustained-release portion is formed to have a diameter of 12 to 20 μm. The mononuclear in a state in which the sustained-release unit is disposed in a collateral circulation path located on the central side of the living body or a peripheral site of the collateral circulation path with respect to the ischemic site formed in the living body. The medical system according to any one of claims 1 to 3, wherein the supply of the sphere is performed over time. The medical system according to any one of claims 1 to 4, wherein the sustained release portion has a long shape that can be wound around the blood vessel and disposed.

Images